Glenmark Pharma Q1 net up 47% at Rs 333 cr on sales growth

Anti diabetes and cardiac drug sales helped beat GST-led slowdown

Glenmark posted 47 per cent increase in consolidated net profit in Q1 FY 18 on the back of growth in sales in domestic and US markets. Net profit for the period was Rs 333 crore as against Rs 226 crore for the same period last year.

Overall revenue rose around 20 per cent to Rs 2,363 crore led by growth in US and domestic market sales. While other companies have seen their domestic sales fall due to good and service tax related de-stocking in June, Glenmark reported 15 per cent growth in its India sales.

Glenmark had seen a modest